Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies

European Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2011, Pages 4897-4903

  Chitra, Selvam ^a   Paul, Nidhin ^b   Muthusubramanian, Shanmugam ^b   Manisankar, Paramasivam ^a   Yogeeswari, Perumal ^c   Sriram, Dharmarajan ^c  

^a ALAGAPPA UNIVERSITY   (India)

^b MADURAI KAMARAJ UNIVERSITY   (India)

^c BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Antimycobacterial activity; Benzo d thiazole; Friedlander annulation; Mycobacterium tuberculosis; Tetrazole; Thiadiazole

Indexed keywords

1,3 BENZOTHIAZOL 2 YL(2,4 DIPHENYL 3 QUINOLYL)SULPHIDE; 1,3 BENZOTHIAZOL 2 YL[2 (4 BROMOPHENYL) 4 PHENYL 3 QUINOLYL]SULPHIDE; 1,3 BENZOTHIAZOL 2 YL[2 (4 CHLOROPHENYL) 4 PHENYL 3 QUINOLYL]SULPHIDE; 1,3 BENZOTHIAZOL 2 YL[2 (4 METHYLPHENYL) 4 PHENYL 3 QUINOLYL]SULPHIDE; 1,3 BENZOTHIAZOL 2 YL[2 (5,8 DIHYDRO 2 NAPHTHALENYL) 4 PHENYL 3 QUINOLYL]SULPHIDE; 2 (2 (BIPHENYL 4 YL) 4 PHENYLQUINOLIN 3 YL THIO) 5 METHYL 1,3,4 THIADIAZOLE; 2 (2 (BIPHENYL 4 YL) 4 PHENYLQUINOLIN 3 YLTHIO)BENZO[D]THIAZOLE; 2 (4 BROMOPHENYL) 4 PHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAAZOL 5 YL)SULFANYL]QUINOLINE; 2 (4 CHLOROPHENYL) 4 PHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAAZOL 5 YL)SULFANYL]QUINOLINE; 2 (4 METHOXYPHENYL) 4 PHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAAZOL 5 YL)SULFANYL]QUINOLINE; 2 (4 METHYLPHENYL) 4 PHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAAZOL 5 YL)SULFANYL]QUINOLINE; 2 (4 METHYLPHENYL) 4 PHENYL 3 QUINOLYL(5 METHYL 1,3,4 THIADIAZOL 2 YL)SULFIDE; 2 (5,8 DIHYDRO 2 NAPHTHALENYL) 4 PHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAAZOL 5 YL)SULFANYL]QUINOLINE; 2 (BIPHENYL 4 YL) 4 PHENYL 3 (1 PHENYL 1H TETRAZOL 5 YLTHIO)QUINOLINE; 2 [2 (4 BROMOPHENYL) 4 PHENYL 3 QUINOLYL]SULFANYL 5 METHYL 1,3,4 THIADIAZOLE; 2 [2 (4 CHLOROPHENYL) 4 PHENYL 3 QUINOLYL]SULFANYL 5 METHYL 1,3,4 THIADIAZOLE; 2 [2 (4 METHOXYPHENYL) 4 PHENYL 3 QUINOLYL]SULFANYL 1,3 BENZOTHIAZOLE; 2 [2 (4 METHOXYPHENYL) 4 PHENYL 3 QUINOLYL]SULFANYL 5 METHYL 1,3,4 THIADIAZOLE; 2 METHYL 5 [2 (2 NAPHTHYL) 4 PHENYL 3 QUINOLYL]SULFANYL 1,3,4 THIADIAZOLE; 2,4 DIPHENYL 3 [(1 PHENYL 1H 1,2,3,4 TETRAZOL 5 YL)SULFANYL]QUINOLINE; 2,4 DIPHENYL 3 QUINOLYL (5 METHYL 1,3,4 THIADIAZOL 2 YL)SULPHIDE; BEDAQUILINE; CIPROFLOXACIN; MEFLOQUINE; MOXIFLOXACIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANNULATION REACTION; ARTICLE; CATALYST; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROBLAST; FRIEDLANDER ANNULATION; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; NIH 3T3 CELLS; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES; TUBERCULOSIS;

EID: 80053190390     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.07.046     Document Type: Article

References (38)

1. D.A. Fidock Nature 465 2010 297 298
2. T.S. Balganesh, P.M. Alzari, and S.T. Cole Trends Pharmacol. Sci. 29 2008 576 581
3. D.B. Young, M.D. Perkins, K. Duncan, and C.E. Barry J. Clin. Invest. 118 2008 1255 1265
4. A.M. Ginsberg, and M. Spigelman Nat. Med. 13 2007 290 294
5. C. Dye, and B.G. Williams Science 328 2010 856 861
6. W.J. Burman Clin. Infect. Dis. 50 2010 S165 S172
7. P. LoBue Curr. Opin. Infect. Dis. 22 2009 167 173
8. Y. Zhang, K. Post-Martens, and S. Denkin Drug Discov. Today 11 2006 21 27
9. E.D. Brown, and G.D. Wright Chem. Rev. 105 2005 759 774
10. M. Balasubramanian, and J.G. Keay A.R. Katritzky, C.W. Rees, E.F.V. Scriven, Comprehensive Heterocyclic Chemistry II vol. 5 1996 Pergamon New York 245 266
11. J.P. Michael Nat. Prod. Rep. 14 1997 605 618
12. A. Kumar, K. Srivastava, R. Kumar, S.K. Puri, and P.M.S. Chauhan Bioorg. Med. Chem. Lett. 20 2010 7059 7063
13. R. Arancibia, F. Dubar, B. Pradines, I. Forfar, D. Dive, A.H. Klahn, and C. Biot Bioorg. Med. Chem. 18 2010 8085 8091
14. P.A. Leatham, H.A. Bird, V. Wright, D. Seymour, and A. Gordon Eur. J. Rheumatol. Inflamm. 6 1983 209 211
15. W. A. Denny, W. R. Wilson, D. C. Ware, G. J. Atwell, J. B. Milbank, R. J. Stevenson. U.S. Patent 7064117 (2006).
16. V.R. Solomon, and C.H.H. Lee Bioorg. Med. Chem. 18 2010 1563 1572
17. A. Mahamoud, J. Chevalier, A. Davin-Regli, J. Barbe, and J.-M. Pages Curr. Drug Targets 7 2006 843 847
18. W.D. Wilson, M. Zhao, S.E. Patterson, R.L. Wydra, L. Janda, and L. Strekowski Med. Chem. Res. 2 1992 102 110
19. L. Strekowski, J.L. Mores, V.A. Honkan, A. Czarny, M.T. Cegla, S.E. Patterson, R.L. Wydra, and R.F. Schinazi J. Med. Chem. 34 1991 1739 1746
20. Guidelines for the Management of Drug-Resistant Tuberculosis WHO/TB/96-210 (Rev.1) 1997 World Health Organization Geneva
21. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Lancet Infect. Dis. 3 2003 432 442
22. S. Jayaprakash, Y. Iso, B. Wan, S.G. Franzblau, and A.P. Kozikowski Chem. Med. Chem. 1 2006 593 597
23. L.E. Bermudez, P. Kolonoski, M. Wu, P.A. Aralar, C.B. Inderlied, and L.S. Young Antimicrob. Agents Chemother. 43 1999 1870 1874
24. L.E. Bermudez, P. Kolonoski, L.E. Seitz, M. Petrofsky, R. Reynolds, M. Wu, and L.S. Young Antimicrob. Agents Chemother. 48 2004 3556 3558
25. L.E. Bermudez, P. Kolonoski, M. Petrofsky, M. Wu, C.B. Inderlied, and L.S. Young J. Infect. Dis. 187 2003 1977 1980
26. J. Mao, Y. Wang, B. Wan, A.P. Kozikowski, and S.G. Franzblau Chem. Med. Chem. 2 2007 1624 1630
27. M. Pieroni, A. Lilienkampf, B. Wan, Y. Wang, S.G. Franzblau, and A.P. Kozikowski J. Med. Chem. 52 2009 6287 6296
28. K. Andries, P. Verhasselt, J. Guillemont, W.H. Gohlmann, J. Neefs, J. Winkler, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Pernot, N. Lounis, and V. Jarlier Science 307 2005 223 227
29. R. Manikannan, S. Muthusubramanian, P. Yogeeswari, and D. Sriram Bioorg. Med. Chem. Lett. 20 2010 3352 3355
30. R. Manikannan, R. Venkatesan, S. Muthusubramanian, P. Yogeeswari, and D. Sriram Bioorg. Med. Chem. Lett. 20 2010 6920 6924
31. M. Barbero, S. Bazzi, S. Cadamuro, and S. Dughera Tetrahedron. Lett. 51 2010 2342 2344 references cited therein
32. Crystallographic data (excluding structure factors) for quinoline 6f in this paper have been deposited with the Cambridge Crystallographic Data Center as supplementary publication numbers CCDC 798947. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)1223 336033 or e-mail: deposit@ccdc.cam.ac.uk ].
33. National Committee for Clinical Laboratory Standards Antimycobacterial Susceptibility Testing for Mycobacterium tuberculosis, Proposed Standard M24-T 1995 National Committee for Clinical Laboratory Standards Villanova, PA
34. T. Mosmann J. Immunol. Methods 65 1983 55 63
35. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, H. Campbell, J. Mayo, and M. Boyd J. Natl. Cancer Inst. 83 1991 757 766
36. S. Saravanan, S. Muthusubramanian, S. Vasantha, S. Sivakoluthu, and P. Raghavaiah J. Sulfur Chem. 28 2007 181 199
37. L. Yimin, and Z. Wei QSAR Comb. Sci. 25 2006 728 731
38. L. Eberhard, and R. Dieter Z. Chem. 15 1975 351 352